Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EBITDA: 2009-2025

Historic EBITDA for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $6.9 million.

  • Gyre Therapeutics' EBITDA rose 63.60% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year increase of 115.81%. This contributed to the annual value of $16.2 million for FY2024, which is 124.04% up from last year.
  • As of Q3 2025, Gyre Therapeutics' EBITDA stood at $6.9 million, which was up 218.98% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' EBITDA ranged from a high of $51.5 million in Q2 2022 and a low of -$91.6 million during Q4 2023.
  • In the last 3 years, Gyre Therapeutics' EBITDA had a median value of $4.2 million in 2024 and averaged -$3.6 million.
  • In the last 5 years, Gyre Therapeutics' EBITDA tumbled by 342.74% in 2021 and then skyrocketed by 358.76% in 2022.
  • Gyre Therapeutics' EBITDA (Quarterly) stood at -$20.3 million in 2021, then fell by 10.57% to -$22.5 million in 2022, then plummeted by 307.98% to -$91.6 million in 2023, then skyrocketed by 100.73% to $665,000 in 2024, then surged by 63.60% to $6.9 million in 2025.
  • Its EBITDA was $6.9 million in Q3 2025, compared to $2.2 million in Q2 2025 and $2.3 million in Q1 2025.